

# Electronic Supplementary Information

## A [4+3] annulation of benzofuran-derived azadienes and $\alpha$ -bromohydroxamates for the synthesis of benzofuran-fused 1,4-diazepinones

Qing-Yun Fang<sup>a</sup> and Li-Ming Zhao<sup>\*,a,b</sup>

<sup>a</sup>School of Chemistry and Materials Science, Jiangsu Normal University, Xuzhou 221116,  
Jiangsu, China

<sup>b</sup>State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of  
Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College,  
Beijing 100050, China

\*E-mail: lmzhao@jsnu.edu.cn

## Table of Contents

1. General Methods .....	S3
2. Synthesis of Product <b>3</b> and Characterization Data.....	S3-S12
3. Gram-Scale Synthesis of Compound <b>3la</b> .....	S12
4. Synthesis of Compound <b>4</b> and Characterization Data.....	S12-S13
5. Synthesis of Compound <b>5</b> and Characterization Data.....	S13-S14
6. References.....	S14
7. Copies of $^1\text{H}$ and $^{13}\text{C}$ NMR Spectra for Compound <b>3</b> .....	S15-S37
8. Copies of $^1\text{H}$ and $^{13}\text{C}$ NMR Spectra for Compound <b>4</b> .....	S38
9. Copies of $^1\text{H}$ and $^{13}\text{C}$ NMR Spectra for Compound <b>5</b> .....	S39
10. Crystal Structure of Compound <b>3aa</b> .....	S40-S41

**General Methods** Solvents were treated prior to use according to the standard methods.

Other reagents were used as purchased without further purification. Reaction progress was monitored by thin-layer chromatography (TLC) on silica gel plates. Chromatographic purification was performed on silica gel columns (100-200 mesh size). Melting points were uncorrected.  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra were recorded at 400 MHz and 100 MHz in  $\text{CDCl}_3$  with chemical shift ( $\delta$ ) given in ppm relative to TMS as the internal standard. Multiplicities were indicated as followed: s (singlet), d (doublet), t (triplet), m (multiplet), dd (doublet of doublets), and so forth; the coupling constant ( $J$ ) was given in hertz (Hz). High-resolution mass spectra (HRMS) were recorded using electrospray ionization (ESI) and time-of-flight (TOF) mass analysis. Benzofuran-derived azadienes (BDAs) **1<sup>1-5</sup>** and  $\alpha$ -bromohydroxamates **2<sup>6,7</sup>** were prepared according to literature procedures.

**General Procedure for the Synthesis of Product 3.** To a solution of benzofuran-derived azadienes **1** (0.1 mmol) and  $\alpha$ -bromohydroxamates **2** (0.12 mmol) in anhydrous MeCN (2 mL) were added  $\text{Cs}_2\text{CO}_3$  (0.12 mmol). The reaction mixture was stirred at room temperature for 1-3 h. After the completion of the reaction, the solid was filtered and washed with dichloromethane, and the combined filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5) to afford product **3**.

*4-(Benzylxy)-5-phenyl-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3aa).* White solid (43 mg, 78% yield); mp 113-115 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.19-8.16 (m, 1H), 7.73 (d,  $J$  = 8.0 Hz, 2H), 7.45-7.38 (m, 3H), 7.33-7.21 (m, 10H), 7.13-7.10

(m, 2H), 5.90 (s, 1H), 4.72 (d,  $J$  = 16.8 Hz, 1H), 4.11 and 4.06 (ABq,  $J$  = 10.0 Hz, 2H), 3.99 (d,  $J$  = 16.8 Hz, 1H), 2.26 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.4, 153.0, 144.8, 144.0, 137.5, 134.5, 134.2, 129.7, 129.0, 128.9, 128.8, 128.5, 126.5, 125.7, 124.5, 123.7, 123.2, 121.6, 111.3, 76.9, 63.5, 54.9, 21.5. HRMS (ESI) m/z calcd for  $\text{C}_{31}\text{H}_{27}\text{N}_2\text{O}_5\text{S}$  [M + H]<sup>+</sup> 539.1641; found 539.1668.

*4-(Benzylxyloxy)-5-(4-fluorophenyl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ba).* White solid (46 mg, 82% yield); mp 114-116 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17-8.15 (m, 1H), 7.73 (d,  $J$  = 8.0 Hz, 2H), 7.45-7.37 (m, 3H), 7.34-7.29 (m, 5H), 7.25-7.21 (m, 2H), 7.11-7.08 (m, 2H), 6.94 (t,  $J$  = 8.8 Hz, 2H), 5.86 (s, 1H), 4.72 (d,  $J$  = 16.8 Hz, 1H), 4.11 and 4.06 (ABq,  $J$  = 10.0 Hz, 2H), 3.96 (d,  $J$  = 16.8 Hz, 1H), 2.27 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.5, 162.7 ( $J$  = 247.3 Hz), 153.0, 144.9, 143.7, 134.4, 134.2, 133.4 ( $J$  = 3.4 Hz), 129.8, 128.9, 128.8, 128.6, 128.5, 124.4, 123.8, 123.2, 121.8, 116.0 ( $J$  = 21.6 Hz), 111.3, 76.9, 62.9, 54.9, 21.5. HRMS (ESI) m/z calcd for  $\text{C}_{31}\text{H}_{25}\text{FN}_2\text{NaO}_5\text{S}$  [M + Na]<sup>+</sup> 579.1366; found 579.1394.

*4-(Benzylxyloxy)-5-(4-chlorophenyl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ca).* White solid (45 mg, 78% yield); mp 120-122 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.19-8.13 (m, 1H), 7.73 (d,  $J$  = 8.4 Hz, 2H), 7.46-7.37 (m, 3H), 7.34-7.29 (m, 5H), 7.25-7.21 (m, 4H), 7.05 (d,  $J$  = 8.4 Hz, 2H), 5.85 (s, 1H), 4.72 (d,  $J$  = 16.8 Hz, 1H), 4.11 and 4.07 (ABq,  $J$  = 10.0 Hz, 2H), 3.94 (d,  $J$  = 16.8 Hz, 1H), 2.28 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.5, 153.0, 144.9, 136.0, 134.9, 134.4, 134.2, 129.8, 129.2, 128.9, 128.9, 128.8, 128.6, 128.0, 125.9, 124.4, 123.8, 123.2, 121.9, 111.3, 77.0, 63.0, 54.9, 21.5. HRMS (ESI) m/z calcd for  $\text{C}_{31}\text{H}_{25}\text{ClN}_2\text{NaO}_5\text{S}$  [M + Na]<sup>+</sup> 595.1070; found 595.1049.

*4-(Benzylxyloxy)-5-(*p*-tolyl)-1-tosyl-1,2,4,5-tetrahydro-3*H*-benzofuro[3,2-*e*][1,4]diazepin-3-one (**3da**)*. White solid (45 mg, 82% yield); mp 124-126 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.18-8.16 (m, 1H), 7.72 (d, J = 8.4 Hz, 2H), 7.45-7.37 (m, 3H), 7.32-7.28 (m, 5H), 7.24-7.21 (m, 2H), 7.05 (d, J = 8.4 Hz, 2H), 6.99 (t, J = 8.4 Hz, 2H), 5.86 (s, 1H), 4.72 (d, J = 16.4 Hz, 1H), 4.08 and 4.04 (ABq, J = 10.0 Hz, 2H), 4.00 (d, J = 16.4 Hz, 1H), 2.27 (s, 3H), 2.26 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 167.4, 153.0, 144.8, 144.2, 138.8, 134.6, 134.2, 129.7, 129.7, 128.9, 128.8, 128.7, 128.5, 126.4, 125.7, 124.5, 123.6, 123.2, 121.5, 111.3, 76.8, 63.3, 54.9, 21.5, 21.0. HRMS (ESI) m/z calcd for C<sub>32</sub>H<sub>28</sub>N<sub>2</sub>NaO<sub>5</sub>S [M + Na]<sup>+</sup> 575.1617; found 575.1638.

*4-(Benzylxyloxy)-5-(4-methoxyphenyl)-1-tosyl-1,2,4,5-tetrahydro-3*H*-benzofuro[3,2-*e*][1,4]diazepin-3-one (**3ea**)*. White solid (49 mg, 86% yield); mp 126-128 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.18-8.16 (m, 1H), 7.72 (d, J = 8.4 Hz, 2H), 7.45-7.37 (m, 3H), 7.34-7.28 (m, 5H), 7.24-7.22 (m, 2H), 7.02 (d, J = 8.8 Hz, 2H), 6.76 (d, J = 8.8 Hz, 2H), 5.96 (s, 1H), 4.73 (d, J = 16.8 Hz, 1H), 4.07 and 4.02 (ABq, J = 10.0 Hz, 2H), 4.01 (d, J = 16.8 Hz, 1H), 3.73 (s, 3H), 2.26 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 167.4, 159.8, 153.0, 144.8, 144.3, 134.6, 134.3, 129.7, 129.6, 128.9, 128.8, 128.7, 128.5, 127.9, 125.7, 124.5, 123.6, 123.1, 121.6, 114.3, 111.3, 76.8, 63.1, 55.3, 54.9, 21.5. HRMS (ESI) m/z calcd for C<sub>32</sub>H<sub>29</sub>N<sub>2</sub>O<sub>6</sub>S [M + H]<sup>+</sup> 569.1746; found 569.1749.

*4-(Benzylxyloxy)-5-(4-(methylthio)phenyl)-1-tosyl-1,2,4,5-tetrahydro-3*H*-benzofuro[3,2-*e*][1,4]diazepin-3-one (**3fa**)*. White solid (48 mg, 82% yield); mp 128-130 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.18-8.14 (m, 1H), 7.73 (d, J = 8.0 Hz, 2H), 7.45-7.38 (m, 3H), 7.33-7.28 (m, 5H), 7.24-7.21 (m, 2H), 7.11 (d, J = 8.4 Hz, 2H), 7.02 (d, J = 8.4 Hz, 2H), 5.85 (s, 1H), 4.72 (d, J =

16.8 Hz, 1H), 4.09 and 4.05 (ABq,  $J$  = 10.0 Hz, 2H), 3.98 (d,  $J$  = 16.4 Hz, 1H), 2.40 (s, 3H), 2.27 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.5, 153.0, 144.8, 143.9, 139.8, 134.5, 134.3, 134.1, 129.8, 128.9, 128.8, 128.6, 127.0, 126.6, 125.8, 124.5, 123.7, 123.2, 121.7, 111.3, 76.9, 63.2, 55.0, 21.5, 15.4. HRMS (ESI) m/z calcd for  $\text{C}_{32}\text{H}_{28}\text{N}_2\text{NaO}_5\text{S}_2$  [M + Na] $^+$  607.1337; found 607.1363.

*5-([1,1'-Biphenyl]-4-yl)-4-(benzyloxy)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ga).* White solid (44 mg, 72% yield); mp 124-126 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.20-8.17 (m, 1H), 7.75 (d,  $J$  = 8.4 Hz, 2H), 7.49-7.45 (m, 5H), 7.43-7.38 (m, 4H), 7.35-7.29 (m, 6H), 7.25-7.23 (m, 2H), 7.18 (d,  $J$  = 8.4 Hz, 2H), 5.94 (s, 1H), 4.75 (d,  $J$  = 16.8 Hz, 1H), 4.13 and 4.09 (ABq,  $J$  = 10.0 Hz, 2H), 4.06 (d,  $J$  = 16.8 Hz, 1H), 2.27 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.5, 153.0, 144.8, 144.0, 141.8, 140.1, 136.4, 134.5, 134.2, 129.8, 128.9, 128.8, 128.6, 127.7, 127.6, 127.0, 127.0, 125.8, 124.5, 123.7, 123.2, 121.7, 111.3, 76.9, 63.3, 55.0, 21.5. HRMS (ESI) m/z calcd for  $\text{C}_{37}\text{H}_{30}\text{N}_2\text{NaO}_5\text{S}$  [M + Na] $^+$  637.1773; found 637.1790.

*4-(Benzyloxy)-5-(3-chlorophenyl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ha).* White solid (42 mg, 74% yield); mp 121-123 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17-8.15 (m, 1H), 7.75 (d,  $J$  = 8.4 Hz, 2H), 7.46-7.39 (m, 3H), 7.34-7.27 (m, 6H), 7.22-7.18 (m, 3H), 7.13 (t,  $J$  = 2.0 Hz, 1H), 6.99 (d,  $J$  = 7.6 Hz, 1H), 5.82 (s, 1H), 4.71 (d,  $J$  = 16.8 Hz, 1H), 4.12 and 4.06 (ABq,  $J$  = 10.0 Hz, 2H), 4.00 (d,  $J$  = 16.8 Hz, 1H), 2.28 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.4, 153.0, 144.9, 143.2, 139.4, 135.0, 134.3, 134.2, 130.3, 129.8, 129.1, 129.0, 128.9, 128.8, 128.6, 126.9, 125.9, 124.7, 124.3, 123.8, 123.2, 121.9, 111.4, 76.7, 63.1, 55.0, 21.5. HRMS (ESI) m/z calcd for  $\text{C}_{31}\text{H}_{25}\text{ClN}_2\text{NaO}_5\text{S}$  [M + Na] $^+$

595.1070; found 595.1068.

*4-(Benzylxyloxy)-5-(3-methoxyphenyl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ia).* White solid (43 mg, 76% yield); mp 125-127 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.17-8.15 (m, 1H), 7.73 (d, *J* = 8.4 Hz, 2H), 7.45-7.36 (m, 3H), 7.32-7.28 (m, 5H), 7.23-7.21 (m, 2H), 7.17 (t, *J* = 8.0 Hz, 1H), 6.80 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.71 (t, *J* = 2.0 Hz, 1H), 6.66 (d, *J* = 8.0 Hz, 1H), 5.84 (s, 1H), 4.71 (d, *J* = 16.4 Hz, 1H), 4.09 (s, 2H), 4.01 (d, *J* = 16.8 Hz, 1H), 3.69 (s, 3H), 2.27 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 167.4, 159.9, 153.0, 144.8, 143.9, 139.1, 134.6, 134.2, 130.1, 129.8, 128.9, 128.8, 128.8, 128.5, 125.7, 124.4, 123.7, 123.2, 121.6, 118.5, 113.7, 113.0, 111.3, 76.9, 63.4, 55.2, 54.9, 21.5. HRMS (ESI) m/z calcd for C<sub>32</sub>H<sub>29</sub>N<sub>2</sub>O<sub>6</sub>S [M + H]<sup>+</sup> 569.1746; found 569.1766.

*4-(Benzylxyloxy)-5-(2-fluorophenyl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ja).* White solid (43 mg, 78% yield); mp 115-117 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03-8.00 (m, 1H), 7.77 (d, *J* = 8.4 Hz, 2H), 7.38-7.28 (m, 9H), 7.21-7.17 (m, 2H), 7.08-6.98 (m, 3H), 6.13 (s, 1H), 4.88 (d, *J* = 17.6 Hz, 1H), 4.53 (d, *J* = 17.2 Hz, 1H), 4.16 (d, *J* = 9.6 Hz, 1H), 3.95 (d, *J* = 9.6 Hz, 1H), 2.30 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 167.2, 160.7 (*J* = 247.8 Hz), 153.3, 144.8, 143.9, 134.7, 134.3, 131.0 (*J* = 8.6 Hz), 129.9, 129.4 (*J* = 3.2 Hz), 128.8, 128.7, 128.5, 128.4, 125.8, 124.8, 124.6 (*J* = 3.6 Hz), 123.9 (*J* = 13.1 Hz), 123.7, 122.4, 121.1, 116.4 (*J* = 2.2 Hz), 111.3, 76.1, 59.0, 55.8, 21.5. HRMS (ESI) m/z calcd for C<sub>31</sub>H<sub>25</sub>FN<sub>2</sub>NaO<sub>5</sub>S [M + Na]<sup>+</sup> 579.1366; found 579.1395.

*4-(Benzylxyloxy)-5-(2-chlorophenyl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ka).* White solid (44 mg, 77% yield); mp 122-124 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98-7.95 (m, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.41 (dd, *J* = 8.0, 1.2 Hz, 1H),

7.37-7.30 (m, 5H), 7.29-7.27 (m, 3H), 7.17-7.10 (m, 3H), 6.95 (dd,  $J$  = 8.0, 1.6 Hz, 1H), 6.46 (s, 1H), 4.86 (d,  $J$  = 17.6 Hz, 1H), 4.66 (d,  $J$  = 17.2 Hz, 1H), 4.25 (d,  $J$  = 9.2 Hz, 1H), 3.77 (d,  $J$  = 9.2 Hz, 1H), 2.31 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.3, 153.4, 144.9, 144.6, 134.7, 134.7, 134.6, 134.1, 130.3, 130.2, 130.0, 129.0, 128.8, 128.6, 128.5, 128.4, 127.4, 125.8, 124.9, 123.7, 122.2, 121.0, 111.4, 76.2, 60.9, 56.2, 21.6. HRMS (ESI) m/z calcd for  $\text{C}_{31}\text{H}_{25}\text{ClN}_2\text{NaO}_5\text{S} [\text{M} + \text{Na}]^+$  595.1070; found 595.1071.

*4-(Benzyl oxy)-5-(2-bromophenyl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3la).* White solid (46 mg, 75% yield); mp 114-116 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.97-7.95 (m, 1H), 7.90 (d,  $J$  = 8.4 Hz, 2H), 7.61-7.59 (m, 1H), 7.36-7.30 (m, 5H), 7.29-7.26 (m, 3H), 7.21-7.15 (m, 2H), 7.13-7.10 (m, 2H), 6.94-6.92 (m, 1H), 6.49 (s, 1H), 4.85 (d,  $J$  = 15.6 Hz, 1H), 4.68 (d,  $J$  = 15.2 Hz, 1H), 4.28 (d,  $J$  = 9.2 Hz, 1H), 3.74 (d,  $J$  = 9.2 Hz, 1H), 2.31 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.3, 153.5, 144.9, 144.8, 136.3, 134.7, 134.0, 133.6, 130.4, 130.0, 129.0, 128.7, 128.6, 128.5, 128.3, 128.0, 125.8, 125.2, 124.9, 123.7, 122.2, 120.9, 111.4, 76.2, 63.4, 56.3, 21.6. HRMS (ESI) m/z calcd for  $\text{C}_{31}\text{H}_{25}\text{BrN}_2\text{NaO}_5\text{S} [\text{M} + \text{Na}]^+$  639.0565; found 639.0593.

*4-(Benzyl oxy)-5-(o-tolyl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ma).* White solid (43 mg, 78% yield); mp 126-128 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.01-7.99 (m, 1H), 7.82 (d,  $J$  = 8.4 Hz, 2H), 7.36-7.31 (m, 4H), 7.29-7.23 (m, 4H), 7.21-7.18 (m, 2H), 7.07-7.00 (m, 3H), 6.76 (d,  $J$  = 8.0 Hz, 1H), 6.11 (s, 1H), 4.72 and 4.71 (ABq,  $J$  = 15.6 Hz, 2H), 4.19 (d,  $J$  = 9.2 Hz, 1H), 3.72 (d,  $J$  = 9.2 Hz, 1H), 2.38 (s, 3H), 2.30 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.9, 153.3, 145.7, 144.9, 137.6, 135.3, 134.7, 134.2, 131.2, 130.0, 129.1, 128.8, 128.7, 128.6, 128.4, 127.3, 126.3, 125.6, 124.9, 123.6, 122.2, 120.9,

111.3, 76.5, 61.0, 56.0, 21.5, 19.8. HRMS (ESI) m/z calcd for C<sub>32</sub>H<sub>28</sub>N<sub>2</sub>NaO<sub>5</sub>S [M + Na]<sup>+</sup>

575.1617; found 575.1631.

*4-(Benzylxy)-5-(naphthalen-1-yl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3na).* White solid (49 mg, 83% yield); mp 115-117 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.17 (d, J = 8.4 Hz, 1H), 8.07 (d, J = 7.6 Hz, 1H), 7.87-7.82 (m, 4H), 7.49 (t, J = 7.2 Hz, 1H), 7.43 (t, J = 7.2 Hz, 1H), 7.37-7.28 (m, 5H), 7.24-7.17 (m, 4H), 6.99 (d, J = 7.2 Hz, 1H), 6.91 (d, J = 7.2 Hz, 2H), 6.66 (s, 1H), 4.78 and 4.69 (ABq, J = 17.2 Hz, 2H), 4.21 (d, J = 9.6 Hz, 1H), 3.81 (d, J = 9.6 Hz, 1H), 2.31 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 167.6, 153.1, 145.1, 144.9, 134.6, 134.2, 134.1, 131.8, 129.9, 128.9, 128.7, 128.7, 128.6, 128.3, 126.6, 126.1, 125.7, 124.9, 124.8, 123.7, 123.6, 122.4, 121.5, 111.3, 77.0, 76.7, 55.8, 21.6. HRMS (ESI) m/z calcd for C<sub>35</sub>H<sub>28</sub>N<sub>2</sub>NaO<sub>5</sub>S [M + Na]<sup>+</sup> 611.1617; found 611.1644.

*4-(Benzylxy)-5-(naphthalen-2-yl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3oa).* White solid (50 mg, 84% yield); mp 114-116 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.23-8.19 (m, 1H), 7.78-7.73 (m, 4H), 7.70-7.68 (m, 1H), 7.48-7.40 (m, 6H), 7.36-7.29 (m, 6H), 7.23-7.21 (m, 2H), 6.04 (s, 1H), 4.72 (d, J = 16.4 Hz, 1H), 4.15 and 4.08 (ABq, J = 10.0 Hz, 1H), 4.06 (d, J = 16.4 Hz, 1H), 2.27 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 167.3, 153.0, 144.8, 144.0, 135.0, 134.5, 134.2, 133.1, 132.9, 129.8, 129.1, 128.9, 128.8, 128.8, 128.6, 128.2, 127.6, 126.8, 126.6, 125.8, 125.7, 124.5, 124.1, 123.7, 123.2, 121.8, 111.4, 77.0, 63.7, 55.0, 21.5. HRMS (ESI) m/z calcd for C<sub>35</sub>H<sub>28</sub>N<sub>2</sub>NaO<sub>5</sub>S [M + Na]<sup>+</sup> 611.1617; found 611.1645.

*4-(Benzylxy)-8-methoxy-5-phenyl-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ta).* White solid (42 mg, 73% yield ); mp 130-132 °C. <sup>1</sup>H NMR (400 MHz,

$\text{CDCl}_3$ )  $\delta$  8.16-8.12 (m, 1H), 7.72 (d,  $J$  = 8.4 Hz, 2H), 7.43-7.33 (m, 3H), 7.30-7.26 (m, 5H), 7.23-7.19 (m, 2H), 7.15 (t,  $J$  = 8.0 Hz, 1H), 6.78 (d,  $J$  = 8.0 Hz, 1H), 6.70 (s, 1H), 6.64 (d,  $J$  = 7.6 Hz, 1H), 5.82 (s, 1H), 4.69 (d,  $J$  = 16.8 Hz, 1H), 4.10 (s, 2H), 4.00 (d,  $J$  = 16.4 Hz, 1H), 3.67 (s, 3H), 2.25 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.4, 160.0, 153.0, 144.8, 144.0, 139.1, 134.7, 134.3, 130.1, 129.8, 128.9, 128.8, 128.7, 128.5, 125.7, 124.5, 123.6, 123.2, 121.6, 118.6, 113.8, 113.0, 111.3, 76.9, 63.5, 55.2, 54.9, 21.5. HRMS (ESI) m/z calcd for  $\text{C}_{32}\text{H}_{29}\text{N}_2\text{O}_6\text{S} [\text{M} + \text{H}]^+$  569.1746; found 569.1746.

*4-Methoxy-5-phenyl-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ab).* White solid (35 mg, 75% yield); mp 110-112 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17-8.14 (m, 1H), 7.64 (d,  $J$  = 8.0 Hz, 2H), 7.47-7.33 (m, 4H), 7.30-7.28 (m, 4H), 7.16-7.12 (m, 2H), 5.93 (s, 1H), 4.76 (d,  $J$  = 16.8 Hz, 1H), 3.99 (d,  $J$  = 16.8 Hz, 1H), 3.09 (s, 3H), 2.38 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.5, 153.1, 144.6, 144.0, 137.3, 134.1, 129.7, 129.1, 128.9, 128.6, 126.6, 125.8, 124.5, 123.7, 123.2, 121.6, 111.3, 61.5, 55.0, 21.5. HRMS (ESI) m/z calcd for  $\text{C}_{25}\text{H}_{23}\text{N}_2\text{O}_5\text{S} [\text{M} + \text{H}]^+$  463.1328; found 463.1312.

*4-Ethoxy-5-phenyl-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ac).* White solid (35 mg, 74% yield); mp 109-111 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.18-8.15 (m, 1H), 7.64 (d,  $J$  = 8.0 Hz, 2H), 7.46-7.44 (m, 1H), 7.42-7.36 (m, 2H), 7.30-7.25 (m, 5H), 7.17-7.12 (m, 2H), 5.92 (s, 1H), 4.72 (d,  $J$  = 16.4 Hz, 1H), 3.95 (d,  $J$  = 16.8 Hz, 1H), 3.23-3.11 (m, 2H), 2.39 (s, 3H), 1.03 (t,  $J$  = 7.2 Hz, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.4, 153.0, 144.5, 144.0, 137.6, 134.1, 129.7, 129.1, 129.1, 128.8, 128.7, 126.5, 125.8, 124.5, 123.7, 123.3, 121.7, 111.3, 70.1, 63.5, 54.9, 21.5, 13.8. HRMS (ESI) m/z calcd for  $\text{C}_{26}\text{H}_{24}\text{N}_2\text{NaO}_5\text{S} [\text{M} + \text{Na}]^+$  499.1304; found 499.1321.

*4-(Allyloxy)-5-phenyl-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one*

**(3ad).** White solid (38 mg, 77% yield); mp 111-113 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17-8.15 (m, 1H), 7.66 (d,  $J = 8.4$  Hz, 2H), 7.46-7.44 (m, 1H), 7.40-7.37 (m, 2H), 7.29-7.26 (m, 5H), 7.17-7.13 (m, 2H), 5.97 (s, 1H), 5.78-5.68 (m, 1H), 5.22-5.19 (m, 2H), 4.71 (d,  $J = 16.4$  Hz, 1H), 3.96 (d,  $J = 16.8$  Hz, 1H), 3.65 (dd,  $J = 11.2, 6.4$  Hz, 1H), 3.54 (dd,  $J = 10.8, 6.0$  Hz, 1H), 2.37 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.5, 153.0, 144.7, 144.0, 137.5, 134.1, 131.6, 129.7, 129.1, 128.9, 128.7, 126.5, 125.8, 124.5, 123.7, 123.2, 121.7, 120.3, 111.3, 75.8, 63.7, 54.9, 21.5. HRMS (ESI) m/z calcd for  $\text{C}_{27}\text{H}_{24}\text{N}_2\text{NaO}_5\text{S} [\text{M} + \text{Na}]^+$  511.1304; found 511.1293.

*4-(Allyloxy)-5-(*p*-tolyl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one*

**(3dd).** White solid (31 mg, 61% yield); mp 107-109 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17-8.14 (m, 1H), 7.66 (d,  $J = 8.0$  Hz, 2H), 7.45-7.43 (m, 1H), 7.40-7.37 (m, 2H), 7.27 (d,  $J = 8.4$  Hz, 2H), 7.08 (d,  $J = 8.0$  Hz, 2H), 7.01 (d,  $J = 8.0$  Hz, 2H), 5.93 (s, 1H), 5.78-5.68 (m, 1H), 5.20 (d,  $J = 11.6$  Hz, 2H), 4.71 (d,  $J = 16.8$  Hz, 1H), 3.97 (d,  $J = 16.4$  Hz, 1H), 3.64 (dd,  $J = 11.2, 6.4$  Hz, 1H), 3.51 (d,  $J = 11.2, 6.4$  Hz, 1H), 2.37 (s, 3H), 2.28 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.4, 153.0, 144.7, 144.2, 138.8, 134.5, 134.2, 131.6, 129.7, 128.7, 126.4, 125.7, 124.5, 123.6, 123.2, 121.6, 120.2, 111.3, 75.8, 63.5, 54.9, 21.5, 21.0. HRMS (ESI) m/z calcd for  $\text{C}_{28}\text{H}_{26}\text{N}_2\text{NaO}_5\text{S} [\text{M} + \text{Na}]^+$  525.1460; found 525.1444.

*4-(Allyloxy)-5-(4-methoxyphenyl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diaz*

**(3ed).** White solid (33 mg, 64% yield); mp 112-114 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.16-8.14 (m, 1H), 7.66 (d,  $J = 8.0$  Hz, 2H), 7.45-7.36 (m, 3H), 7.27 (d,  $J = 8.8$  Hz, 2H), 7.06 (d,  $J = 8.4$  Hz, 2H), 6.79 (d,  $J = 8.8$  Hz, 2H), 5.91 (s, 1H), 5.78-5.68 (m, 1H), 5.21

(d,  $J = 11.6$  Hz, 2H), 4.71 (d,  $J = 16.4$  Hz, 1H), 3.97 (d,  $J = 16.4$  Hz, 1H), 3.75 (s, 3H), 3.64 (dd,  $J = 11.2, 6.4$  Hz, 1H), 3.51 (dd,  $J = 11.2, 6.4$  Hz, 1H), 2.37 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.5, 159.8, 153.0, 144.7, 144.3, 134.2, 131.6, 129.7, 129.6, 128.7, 127.9, 125.7, 124.5, 123.7, 123.2, 121.6, 120.2, 114.3, 111.3, 75.8, 63.3, 55.3, 54.9, 21.5. HRMS (ESI) m/z calcd for  $\text{C}_{28}\text{H}_{27}\text{N}_2\text{O}_6\text{S} [\text{M} + \text{H}]^+$  519.1590; found 519.1572.

*4-(Allyloxy)-5-(4-(methylthio)phenyl)-1-tosyl-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3fd).* White solid (33 mg, 62% yield); mp 113-115 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.16-8.14 (m, 1H), 7.67-7.65 (m, 2H), 7.46-7.38 (m, 3H), 7.28 (d,  $J = 8.4$  Hz, 2H), 7.14 (d,  $J = 8.4$  Hz, 2H), 7.05 (d,  $J = 8.4$  Hz, 2H), 5.92 (s, 1H), 5.78-5.68 (m, 1H), 5.24-5.19 (m, 2H), 4.71 (d,  $J = 16.8$  Hz, 1H), 3.94 (d,  $J = 16.8$  Hz, 1H), 3.65 (dd,  $J = 11.2, 6.4$  Hz, 1H), 3.52 (dd,  $J = 11.2, 6.4$  Hz, 1H), 2.42 (s, 3H), 2.37 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.5, 153.0, 144.7, 143.9, 139.8, 134.1, 134.0, 131.5, 129.7, 128.7, 127.0, 126.6, 125.8, 124.5, 123.7, 123.2, 121.7, 120.3, 111.3, 75.8, 63.4, 54.9, 21.5, 15.4. HRMS (ESI) m/z calcd for  $\text{C}_{28}\text{H}_{26}\text{N}_2\text{NaO}_5\text{S}_2 [\text{M} + \text{Na}]^+$  557.1181; found 557.1166.

*4-(Benzyoxy)-5-phenyl-1-(phenylsulfonyl)-1,2,4,5-tetrahydro-3H-benzofuro[3,2-e][1,4]diazepin-3-one (3ua).* White solid (42 mg, 81% yield); mp 113-115 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.20-8.17 (m, 1H), 7.86 (dd,  $J = 7.2, 1.6$  Hz, 2H), 7.59-7.55 (m, 3H), 7.46-7.39 (m, 3H), 7.33-7.29 (m, 3H), 7.28-7.25 (m, 3H), 7.22-7.19 (m, 2H), 7.13-7.10 (m, 2H), 5.88 (s, 1H), 4.74 (d,  $J = 16.4$  Hz, 1H), 4.07-4.00 (m, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  167.4, 153.0, 144.1, 137.5, 137.2, 134.4, 133.6, 129.2, 129.0, 128.8, 128.8, 128.7, 128.5, 126.5, 125.8, 124.3, 123.7, 123.1, 121.5, 111.3, 76.8, 63.5, 55.0. HRMS (ESI) m/z calcd for  $\text{C}_{30}\text{H}_{24}\text{N}_2\text{NaO}_5\text{S} [\text{M} + \text{Na}]^+$  547.1304; found 547.1297.

**Gram-Scale Synthesis of Compound 3la.** To a solution of compound **1I** (1.04 g, 2.3 mmol) and *N*-(benzyloxy)-2-bromoacetamide **2a** (0.67 g, 2.76 mmol) in anhydrous MeCN (5 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (0.91 g, 2.8 mmol). The resulting mixture was stirred at room temperature for 1 h. After the completion of the reaction, the solid was filtered and washed with 2-3 mL of dichloromethane (10 mL), and the combined filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5) to afford the product **3la** as a white solid (1.08 g, 76% yield).


**Synthesis of Compound 4.** To a solution of compound **3la** (61.6 mg, 0.1 mmol) in MeCN/H<sub>2</sub>O (9:1, 2 mL) was added Mo(CO)<sub>6</sub> (60.7 mg, 0.23 mmol). The reaction mixture was stirred and heated to 85 °C for 3 h under nitrogen (monitored by TLC). After the completion of the reaction, the mixture was filtered through a pad of Celite. The filter cake was washed with 2-3 mL of ethyl acetate (10 mL), and the combined filtrates were evaporated to afford a crude product that was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5) to afford the compound **4** as a white solid (39.3 mg, 77% yield); mp 113-115 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.15-8.11 (m, 1H), 7.60 (d, *J* = 8.0 Hz, 3H), 7.41-7.31 (m, 3H), 7.26 (d, *J* = 8.4 Hz, 2H), 7.23-7.15 (m, 2H), 6.49 (dd, *J* = 7.2, 2.0 Hz, 1H), 5.86 (d, *J* = 4.4 Hz, 1H), 5.63 (d, *J* = 3.6 Hz, 1H), 4.57 (d, *J* = 16.8 Hz, 1H), 4.40 (d, *J* = 16.4 Hz, 1H), 2.42 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.5, 153.1, 144.5, 144.3, 137.8, 133.6, 133.0, 130.6, 129.3, 128.6, 128.5, 128.1, 125.8, 125.0, 123.8, 123.8, 123.0, 122.8, 111.3, 56.5, 54.6, 21.7. HRMS (ESI) m/z calcd for C<sub>24</sub>H<sub>18</sub>BrN<sub>2</sub>O<sub>4</sub>S [M - H]<sup>+</sup> 509.0171; found 509.0192.

**Synthesis of Compound 5.** To a solution of compound **4** (51.1 mg, 0.1 mmol) in THF (1 mL) was added K<sub>2</sub>CO<sub>3</sub> (16.6 mg, 0.12 mmol,) and MeI (7.5 μL, 0.12 mmol). The resulting


mixture was stirred at room temperature for 6 h (monitored by TLC). After the completion of the reaction, the mixture was quenched with water and extracted with ethyl acetate (3 X 5 mL). The combined organic layers were dried and concentrated under reduced pressure followed by silica gel column chromatography purification (ethyl acetate/petroleum ether = 1:5) to give the compound **5** as a white solid (33.1 mg, 63% yield); mp 106-108 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (d, *J* = 7.2 Hz, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.59 (d, *J* = 8.0 Hz, 2H), 7.36-7.28 (m, 5H), 7.25-7.16 (m, 2H), 6.91 (d, *J* = 8.0 Hz, 1H), 5.77 (s, 1H), 4.99 (d, *J* = 16.8 Hz, 1H), 4.50 (d, *J* = 17.2 Hz, 1H), 2.45 (s, 3H), 2.28 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 167.5, 153.3, 145.7, 144.4, 137.1, 133.6, 133.6, 130.4, 129.4, 128.6, 128.1, 128.1, 125.6, 125.0, 124.2, 123.7, 122.1, 121.0, 111.3, 62.2, 58.1, 36.2, 21.6. HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>21</sub>BrN<sub>2</sub>NaO<sub>4</sub>S [M + Na]<sup>+</sup> 547.0303; found 547.0315.

## References


- [1] Rong, Z. Q.; Wang, M.; Chow, C. H. E.; Zhao, Y. *Chem. Eur. J.* **2016**, 22, 9483-9487.
- [2] Gu, Z.; Zhou, J.; Jiang, G.-F.; Zhou, Y.-G. *Org. Chem. Front.* **2018**, 5, 1148-1151.
- [3] Marques, A.-S.; Duhail, T.; Marrot, J.; Chataigner, I.; Coeffard, V.; Vincent, G.; Moreau, X. *Angew. Chem. Int. Ed.* **2019**, 58, 9969-9973.
- [4] Trost, B. M.; Zuo, Z. *Angew. Chem. Int. Ed.* **2020**, 59, 1243-1247.
- [5] Fang, Q.-Y.; Yi, M.-H.; Wu, X.-X.; Zhao, L.-M. *Org. Lett.* **2020**, 22, 5266-5270.
- [6] Zhou, J.; Zhang, H.; Chen, X.-L.; Qu, Y.-L.; Zhu, Q.; Feng, C.-G.; Chen, Y.-J. *J. Org. Chem.* **2019**, 84, 9179-9187.
- [7] Jin, Q.; Zhang, D.; Zhang, J. *Org. Biomol. Chem.* **2019**, 17, 9708-9711.




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound **3aa**




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound **3aa**




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3ba




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3ba




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3ca




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3ca




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3da




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3da




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound **3ea**




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3ea




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3fa




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3fa




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3ga




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3ga




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound **3ha**




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound **3ha**




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3ia




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3ia




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound **3ja**




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3ja




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3ka





<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3ka




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3la




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3la




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3ma




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3na





<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3na




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3oa




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3oa







<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound **3ab**




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound **3ab**




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3ac




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3ac




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound **3ad**




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound **3ad**




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3dd




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3dd




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3ed




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3ed




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 3fd




<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 3fd




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound **3ua**





<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound **3ua**




<sup>1</sup>H NMR Spectrum (400 MHz, CDCl<sub>3</sub>) of Compound 4



<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 4



<sup>13</sup>C NMR Spectrum (100 MHz, CDCl<sub>3</sub>) of Compound 5



**Figure S1.** Crystal Structure of **3aa** (50% probability level for the thermal ellipsoids).

**Table S1.** Crystal Data for Compound 3aa

Formula	C <sub>31</sub> H <sub>26</sub> N <sub>2</sub> O <sub>5</sub> S
Formula weight	538.60
Temperature	293 (2) K
Wavelength	0.71073 Å
Crystal system	triclinic
Space group	P-1
Unit cell dimensions	$a = 9.9502$ (7) Å, $\alpha = 113.915$ (6) deg. $b = 11.9913$ (7) Å, $\beta = 96.434$ (6) deg. $c = 14.0968$ (10) Å, $\gamma = 93.254$ (5) deg.
Volume	1518.19 (19) Å <sup>3</sup>
Z	2
Density (calculated)	1.178 g / cm <sup>3</sup>
Absorption coefficient	0.146 mm <sup>-1</sup>
$F(000)$	564.0
Crystal	0.22 x 0.19 x 0.12 mm
Theta range for data collection	5.572 to 48.994 deg
Limiting indices	-11<=h<=10, -13<=k<=13, -16<=l<=14
Reflections collected	10614
Independent reflections	5045 [R(int) = 0.0274, Rsigma = 0.0447]
Data / restraints / parameters	5045 / 0 / 353
Goodness-of-fit on $F^2$	1.048
Final $R$ indices [ $I > 2\sigma(I)$ ]	$R_1 = 0.0677$ , $wR_2 = 0.1935$
$R$ indices (all data)	$R_1 = 0.0846$ , $wR_2 = 0.2084$
Largest diff. peak and hole	0.70 and -0.68 e. Å <sup>-3</sup>